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OBJECTIVE — To determine whether obesity increases platelet reactivity and thrombin ac-
tivity in patients with type 2 diabetes plus stable coronary artery disease.
RESEARCH DESIGN AND METHODS — We assessed platelet reactivity and markers
of thrombin generation and activity in 193 patients from nine clinical sites of the Bypass Angio-
plasty Revascularization Investigation 2 Diabetes (BARI 2D). Blood taken at the time of enroll-
mentwasusedforassayoftheconcentrationofprothrombinfragment1.2(PT1.2,releasedwhen
prothrombin is activated) and ﬁbrinopeptide A (FPA, released when ﬁbrinogen is cleaved).
Platelet activation was identiﬁed with the use of ﬂow cytometry in response to 0, 0.2, and 1
mol/l adenosine diphosphate (ADP).
RESULTS — Concentrations of FPA, PT1.2, and platelet activation in the absence of agonist
were low. Greater BMI was associated with higher platelet reactivity in response to 1 m ADP as
assessed by surface expression of P-selectin (r  0.29, P  0.0001) but not reﬂected by the
binding of ﬁbrinogen to activated glycoprotein IIb-IIIa. BMI was not associated with concentra-
tions of FPA or PT1.2. Platelet reactivity correlated negatively with A1C (P  0.04), was not
related to the concentration of triglycerides in blood, and did not correlate with the concentra-
tion of C-reactive peptide.
CONCLUSIONS — AmongpatientsenrolledinthissubstudyofBARI2D,agreaterBMIwas
associated with higher platelet reactivity at the time of enrollment. Our results suggest that
obesity and insulin resistance that accompanies obesity may inﬂuence platelet reactivity in
patients with type 2 diabetes.
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A
pro-thrombotic state is seen in pa-
tientswithdiabetesandcontributes
to an increased rate of progression
ofatherosclerosisaswellastoexaggerated
thrombosis in response to rupture of an
atherosclerotic plaque (1). Thus, diabetes
isassociatedwithmoreextensivevascular
disease(2)andagreaterburdenofthrom-
bus and associated risk of arterial occlu-
sion after rupture of an atherosclerotic
plaque (3). The pro-thrombotic state re-
ﬂects increased activity of platelets (4,5),
increased activity of the coagulation cas-
cade, and impaired ﬁbrinolysis (1,6,7).
The Bypass Angioplasty Revascular-
ization Investigation 2 Diabetes (BARI
2D) study was designed to simulta-
neously compare the effect on total mor-
tality of 1) revascularization combined
with aggressive medical treatment as op-
posed to aggressive medical treatment
alone with deferred revascularization as
needed and 2) an insulin sensitization
strategyofglycemiccontrolasopposedto
an insulin-providing strategy of glycemic
control (8). A total of 2,368 patients with
type 2 diabetes were enrolled at 49 clini-
cal centers throughout North America,
South America, and Europe. For this sub-
study of BARI 2D, 201 subjects were en-
rolledatnineclinicalcenters.Weassessed
platelet reactivity with the use of ﬂow cy-
tometry and activity of the coagulation cas-
cade by measuring the concentration in
blood of ﬁbrinopeptide A (FPA, released
during the generation of ﬁbrin) and pro-
thrombin fragment 1.2 (PT1.2, released
during the generation of thrombin). In this
study, we sought to identify clinical charac-
teristicsthatinﬂuenceplateletreactivityand
thrombin activity in patients with diabetes
and stable coronary artery disease. We hy-
pothesized that obesity, which is associated
withinsulinresistance,increasesplateletre-
activity in patients with diabetes in a man-
ner similar to that seen in individuals
without diabetes (9,10).
RESEARCH DESIGN AND
METHODS— Centers participating
in BARI 2D were invited to participate in
this substudy, and nine clinical centers
(please see ACKNOWLEDGMENTS) agreed. All
patients enrolled at each participating cen-
ter were eligible to participate in this sub-
study. Written informed consent for
participation in the substudy was obtained
fromeachparticipant,andtheprotocolwas
reviewed by the institutional review board
of each participating clinical center. Results
were reviewed by the data and safety mon-
itoring board of the parent BARI 2D study.
Assessment of platelet reactivity
Blood was obtained with the use of a two-
syringe technique in which the ﬁrst 3 ml
blood was discarded. Blood (1 ml) to be
analyzedforplateletreactivitywasantico-
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hibitor (CTI; Enzyme Research, South
Bend, IN). CTI is a speciﬁc inhibitor of
Factor XIIa without effect on other coag-
ulation factors (11) and was used as the
anticoagulant because we have shown
thattheactivationofplateletsisalteredby
conventional anticoagulants such as ci-
trate (12).
Activation of platelets was identiﬁed
with the use of ﬂow cytometry by the
binding to platelets of ﬂuorescein isothio-
cyanate–labeled ﬁbrinogen (that binds to
the activated conformer of glycoprotein
IIb-IIIa) and phycoerythrin-labeled anti-
CD62 that binds to P-selectin on the
surface of activated platelets (Becton
Dickinson) as previously described
(5,13,14). Platelets were identiﬁed based
on size and binding of a peridinin chloro-
phyll protein (PerCP)-labeled anti-CD61
(Becton Dickinson), which binds to gly-
coprotein IIIa regardless of activation and
does not interfere with the binding of
ﬁbrinogen.
Toquantifynonspeciﬁcassociationof
proteins with platelets and to deﬁne a
threshold above which activation-
dependent association occurs, control
samples containing phycoerythrin-
conjugated nonimmune mouse IgG and
ﬂuorescein isothiocyanate–conjugated
albumin were assayed in samples from
each subject. Assays were performed in
duplicate. Activation of platelets was re-
ported as the percentage of platelets that
bound ﬂuorescein isothiocyanate–
ﬁbrinogen or phycoerythrin–anti-CD62.
This measure of platelet activation corre-
lates with subsequent cardiac risk (13)
and with platelet activation reported as
the mean ﬂuorescence intensity (14).
FPA and PT1.2
Blood to be analyzed for PT1.2 and FPA
was added immediately to SCAT-1 tubes
(Hematologic Technologies, Essex, VT).
These tubes prevent protease activity and
activation of coagulation factors. Aliquots
of plasma were stored at 80°C until
assay.
Concentrations of PT1.2 and FPA
weredeterminedwiththeuseofcommer-
cial enzyme-linked immunosorbent assay
(ELISA) kits (Dade Behring [Marburg,
Germany] for PT1.2 and Vitro Chemie
[Toernooiveld, the Netherlands] for
FPA).
Biochemical parameters
Concentrations of C-reactive protein
(CRP) were determined with the use of a
high-sensitivity colorimetric competitive
ELISA as previously described (15). Con-
centrationsofinsulinweredeterminedby
ELISA (ALPCO, Salem, NH). Concentra-
tions of ﬁbrinogen were determined by
nephelometry (Siemens Healthcare Diag-
nostics, Deerﬁeld, IL).
Fasting lipid proﬁle and A1C assays
were performed by the Biochemistry Core
Laboratory at the University of Minnesota,
Minneapolis. Triglycerides were analyzed
enzymatically. A1C concentrations were
analyzed by high-performance liquid
chromatography. For those patients for
whom the core lab measures were un-
available, an estimate based on site-
speciﬁc regression of the clinical site
measure was used. This estimation was
used for 2.5% of the triglycerides samples
and 0.5% for A1C samples.
Analysis of data
We report results from patients in which
at least 80% of signiﬁcant baseline data
points were available for analysis (n 
201). Patients treated with either ticlopo-
dine or clopidogrel were excluded from
this analysis (n  8) because a primary
measure was ADP-induced activation of
platelets. This study group (n  193) en-
abledustoidentifyfor1SDchangeinthe
independent variable a regression coefﬁ-
cient of 0.20 for 1 SD change in a depen-
dent variable with a power of 0.77.
Because platelet reactivity results and
those for markers of thrombosis were not
Table 1—Demographic and clinical characteristics
Female (%) 31.8
Age at study entry (years) 62.5  9.1
Duration of diabetes (years) 10.0  8.7
Hypertension requiring treatment (%) 84.0
History of myocardial infarction (%) 37.0
Prior coronary artery bypass grafting (%) 2.0
Prior percutaneous coronary intervention (%) 19.9
Current smoker (%) 6.0
BMI 30.5  5.4
BMI categories (%)
Low, 20 1.0
Normal, 20 to 25 11.0
Overweight, 25 to 30 37.0
Class 1 obesity, 30 to 35 33.0
Class 2 obesity, 35 to 40 11.5
Class 3/4 obesity, 40 6.5
Waist circumference (cm) 104.8  13.1
Metabolic syndrome (%) 93.0
PVD (%) 32.1
A1C (%) 7.8  1.7
Total cholesterol (mg/dl) 172  41
Triglycerides (mg/dl) median (Q1–Q3) 179 (108–212)
HDL cholesterol (mg/dl) 37  9
LDL cholesterol (mg/dl) 101  34
Systolic blood pressure 139.3  24.7
Diastolic blood pressure 80.2  14.3
Blood pressure 130/80 mmHg (%) 62.3
Heart rate (bpm) 68.3  12.3
Baseline medications (%)
Aspirin 89.4
	-Blocker 72.6
Calcium-channel blocker 29.9
ACE/angiotensin receptor blocker 71.1
Nitrates 40.8
Statin 72.6
Insulin 25.9
Oral hypoglycemic 81.1
Data are means  SD unless otherwise stated. n  193. Metabolic syndrome is deﬁned by two of the
following: large waist circumference, high triglycerides, low HDL cholesterol, or high blood pressure. PVD
is deﬁned as any of ABI 0.9, carotid stent, carotid disease, carotid surgery, intermittent claudication, and
non-coronary vascular surgery. IQR, interquartile range; Q1, ﬁrst quartile; Q3, third quartile.
Schneider and Associates
DIABETES CARE, VOLUME 32, NUMBER 5, MAY 2009 945normally distributed, Spearman’s rank
correlation estimates were used to evalu-
ate relationships among the thrombosis
markersandothervariablesofinterestin-
cludingBMI,A1C,lipids,andinsulin.AP
value of 0.05 was considered signiﬁcant.
RESULTS
Patient characteristics
Clinical characteristics of patients are
shown in Table 1.
Markers of thrombosis and platelet
reactivity
Evidence of thrombin generation (PT1.2)
and thrombin activity (FPA) was limited
in these patients with stable coronary ar-
tery disease (Table 2). Similarly, evidence
of platelet activation in the absence of ag-
onist was minimal, whether assessed by
the percentage of platelets that bound ﬁ-
brinogen (reﬂecting activation of glyco-
protein IIb-IIIa) or the surface expression
of P-selectin (Table 2). The concentration
of ﬁbrinogen correlated positively with
that of PT1.2 (r  0.17, P  0.034) but
did not correlate with the concentration
of FPA (P  0.24).
Toassessthepropensityofplateletsto
activate in response to a stimulus (i.e.,
platelet reactivity), platelets were stimu-
lated with 0.2 and 1 mol/l ADP (Fig. 1).
The activation of platelets identiﬁed by
the surface expression of P-selectin in the
absence of agonist and in the presence of
0.2 and 1 mol/l ADP correlated posi-
tively (the correlation coefﬁcient between
0.2 and 1 mol/l ADP was 0.85, between
no agonist and 0.2 mol/l was 0.58, and
between no agonist and 1 mol/l ADP
was 0.51; for each association, P 
0.0001). Correlations between the activa-
tion of glycoprotein IIb-IIIa seen with
each concentration of ADP were not as
strong but were still positive. The corre-
lation coefﬁcient between the percentage
ofplateletsthatboundﬁbrinogenwithno
agonist and in response to 0.2 mol/l
ADP was 0.31; between 0.2 and 1 mol/l
ADP, it was 0.64 (P  0.0001 for both).
Thecorrelationcoefﬁcientbetweennoag-
onist and 1 mol/l ADP was 0.12 (P 
0.12).
Correlation between platelet
reactivity, thrombin activity, and
BMI
Greater BMI was associated with greater
platelet reactivity as assessed by the sur-
faceexpressionofP-selectin(Fig.2).After
adjustment for age, sex, A1C, use of insu-
lin, and duration of diabetes in a linear
model of platelet reactivity, the relation-
ship between platelet reactivity and BMI
remained signiﬁcant (Table 3). A similar
magnitude of increase was seen in the
small group (n  19) of subjects who
were not taking aspirin at the time when
blood was taken (data not shown). Iden-
tiﬁcation of platelet activation based on
the binding of ﬁbrinogen (activation of
glycoprotein IIb-IIIa) did not correlate
with BMI. The concentration of FPA and
PT1.2didnotcorrelatewithBMI.Bycon-
trast, the concentration of ﬁbrinogen cor-
related with BMI (r  0.21, P  0.004).
Obesity has been associated with
poor glycemic control, hypertriglyceride-
mia, inﬂammation (reﬂected by an in-
creased CRP), and insulin resistance
(16,17). A1C correlated negatively with
platelet reactivity in response to 1.0
mol/l ADP (
s  0.16, P  0.04). The
effects of A1C and BMI were indepen-
dent. The concentration in blood of trig-
lycerides was not correlated with platelet
reactivity. Similarly, the concentration of
CRP did not correlate with platelet reac-
tivity.Thefastingconcentrationofinsulin
did not correlate with platelet reactivity
(rs  0.14, P  0.07).
CONCLUSIONS — In this substudy
of BARI 2D, we assessed markers of
thrombin generation and activity as well
Figure 1—Distribution of platelet activation in response to ADP. The activation of platelets
inducedby0.2mol/lADPand1mol/lADPwasquantiﬁedwiththeuseofﬂowcytometrybased
onthesurfaceexpressionofP-selectinorthebindingofﬂuorochrome-labeledﬁbrinogen.Eachbox
plotofthedistributionofthepercentageofplateletsactivatedshowsthemedian(line),the25thand
75th percentile (box), and the 10th and 90th percentile (error bars).
Table 2—Biochemical markers
n Median First quartile Third quartile
PT 1.2 (mmol/l) 161 0.84 0.60 1.26
FPA (ng/ml) 127 6.75 3.92 17.36
Fibrinogen 191 361 308 415
P-selectin 0 mol/l ADP 180 0.1 0.0 0.4
P-selectin 0.2 mol/l ADP 180 1.8 0.70 4.45
P-selectin 1 mol/l ADP 180 7.90 3.00 19.85
Fibrinogen binding 0 mol/l ADP 180 0.85 0.10 2.80
Fibrinogen binding 0.2 mol/l ADP 180 17.55 9.30 30.45
Fibrinogen binding 1 mol/l ADP 180 58.05 38.60 77.70
CRP (g/ml) 191 2.05 0.73 5.06
Triglycerides (mg/dl) 193 146 108 212
A1C (%) 293 7.6 6.3 8.9
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tients with type 2 diabetes and stable cor-
onary artery disease. Activity of the
coagulation cascade was limited, as was
evidence of platelet activation in the ab-
sence of agonist. We assessed platelet re-
activity by determining the propensity of
platelets to activate in response to an ag-
onist (0.2 and 1 mol/l ADP). We found
that greater BMI was associated with pro-
gressively greater platelet reactivity when
platelet activation was assessed by the
surface expression of P-selectin induced
by 1 mol/l ADP. A1C correlated nega-
tively with this measure of platelet reac-
tivity. Triglycerides did not correlate with
platelet reactivity. Thus, our results sug-
gest that obesity increases platelet P-
selectinexpressioninpatientswithtype2
diabetes.
Increased platelet reactivity has been
associated with a greater risk of subse-
quent cardiac events in apparently
healthy subjects (18), in patients with
previous myocardial infarction (19), and
in patients undergoing percutaneous cor-
onary intervention (13). Our results sug-
gest that obesity may increase further the
risk of subsequent cardiovascular events
in patients with type 2 diabetes by in-
creasing platelet reactivity.
Consistent with our results, previous
studies have demonstrated increased ac-
tivation of platelets in obese subjects. In
one study, platelet activation was identi-
ﬁed based on measurement of a throm-
boxane metabolite in urine and the
concentration in blood of the CD40 li-
gand. Both were increased in obese com-
pared with lean women, and successful
weight loss led to decreased concentra-
tionsofthesemarkers(9).Asecondstudy
quantiﬁed the concentration in blood of
platelet-derived microparticles that are
released during the activation of platelets.
The concentration of microparticles was
increased in obese patients (10). Similar
to the previous study, the concentration
of microparticles decreased after weight
reduction (10). Accordingly, obese sub-
jects without diabetes manifest evidence
of greater activation of platelets. Our
results are consistent with and extend
these observations to patients with type 2
diabetes.
Aspirin was used in the majority
(89%) of the subjects we studied. The re-
lationship between obesity and platelet
reactivity was of similar magnitude in pa-
tients regardless of aspirin use or nonuse.
These results are consistent with the lim-
ited efﬁcacy of aspirin in patients with di-
abetes (20). One mechanism that may
contribute to limited efﬁcacy of antiplate-
let therapy in such patients is persistently
increased platelet reactivity. Our results
suggestthatobesitymaybeacauseofper-
sistently increased platelet reactivity in
patients with diabetes and thereby con-
tribute to a lack of efﬁcacy of aspirin.
Wedidnotidentifyanassociationbe-
tween the concentration in blood of CRP
and platelet reactivity. By contrast, evi-
dence of platelet activation has been asso-
ciated with concentrations of CRP in
obese women without diabetes (21). In
ourstudy,allpatientshadtype2diabetes,
and platelet reactivity was assessed ex
vivo.Thepreviousstudycomparedmark-
ers of platelet activation in vivo in obese
and nonobese women without diabetes.
In addition, the consistent use of statins
may have decreased CRP and obscured a
potential interaction (22). Thus, differ-
ences in the clinical characteristics of pa-
tients and the methods used to assess
platelet reactivity may account for the
lack of association in our study.
Figure 2—Correlation between the activation of platelets identiﬁed by the surface expression of
P-selectin in response to 1 mol/l ADP and BMI in patients with diabetes. Because the activation
of platelets was not normally distributed, the results were log transformed. Pearson correlation
coefﬁcient and P value are shown. The inset is a box plot showing the distribution of platelet
activation in patients with a lean BMI (25 kg/m
2), overweight patients (BMI 25–30 kg/m
2),
obese patients (BMI 30–35 kg/m
2), and morbidly obese patients (35 kg/m
2). A stepwise incre-
ment was seen with increasing BMI (P  0.02).
Table 3—Linear model of log (platelet surface expression of P-selectin [activation]) in re-
sponse to 1 mol/l ADP
Coefﬁcient from multivariable model P
R
2  0.1169
BMI (per 5 units) 0.27 0.0002
Age (per 10 years) 0.05 0.60
Female sex 0.15 0.37
A1C 0.10 0.044
Insulin use 0.14 0.48
Diabetes duration (years) 0.006 0.55
n  179.
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sure insulin sensitivity, obesity and in-
creased concentrations of insulin in
fasting blood have been associated with
insulin resistance (16). The strong posi-
tiveassociationthatweobservedbetween
obesityandplateletreactivityisconsistent
with our hypothesis that insulin sensitiv-
ity inﬂuences platelet reactivity when
identiﬁedbasedonthesurfaceexpression
of P-selectin and only in response to 1
mol/l ADP. This correlation was not ap-
parent when activation of platelets was
identiﬁed based on the binding of ﬁbrin-
ogen.Themechanismresponsibleforthis
difference is not apparent. However, we
have previously observed that platelet ac-
tivation identiﬁed based on surface ex-
pression of P-selectin is altered by
associated conditions or treatments
(5,23). One mechanism potentially con-
tributing is that activation of glycoprotein
IIb-IIIa occurs with a low concentration
of agonist (13). Thus, the low threshold
for activation of glycoprotein IIb-IIIa may
limit sensitivity for detection of changes.
As seen in Fig. 1, surface expression of
P-selectin was limited in response to 0.2
mol/l ADP. Thus, the discrimination of
inter-individual differences is reduced
when the range of platelets activated is
limited. Accordingly, we postulate that
the lack of statistical signiﬁcance between
BMI and surface expression of P-selectin
in response to 0.2 mol/l ADP reﬂected
the limited discrimination between indi-
viduals because of the limited range of
activation.
Our study does not identify the
mechanism by which insulin resistance
increases platelet reactivity. Previous
work has associated obesity with im-
paired synthesis and activity of cyclic
nucleotides (i.e., cyclic adenosine
monophosphate and cyclic guanosine
monophosphate), which are key signal-
ing molecules involved in the activation
of platelets (24).
In summary, we found that obesity is
associated with greater platelet reactiv-
ity in patients with type 2 diabetes and
stable coronary artery disease. Our re-
sults extend previous observations
made in subjects without diabetes to
subjects with diabetes and suggest that
insulin resistance that is associated with
obesity increases platelet reactivity that
may in turn increase the risk of subse-
quent cardiac events in patients with
type 2 diabetes.
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